Cisterna Magna
Fourth Ventricle
Dandy-Walker Syndrome
Vasospasm, Intracranial
Subarachnoid Space
Paraparesis, Spastic
Subarachnoid Hemorrhage
Basilar Artery
Platybasia
Cerebral Ventricles
Arnold-Chiari Malformation
Cerebrospinal Fluid
Injections, Spinal
Septum of Brain
Echoencephalography
Intracranial Pressure
Syringomyelia
Cranial Fossa, Posterior
Golgi Apparatus
Ultrasonography, Prenatal
Fetal Diseases
Hydrocephalus
Fasciolidae
Dogs
Pregnancy Trimester, Second
Cats
Rabbits
Microscopy, Electron
Brain
Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. (1/221)
1. The aim of the present study was to analyse the cardiovascular actions of the synthetic CB1/CB2 cannabinoid receptor agonist WIN55212-2, and specifically to determine its sites of action on sympathetic cardiovascular regulation. 2. Pithed rabbits in which the sympathetic outflow was continuously stimulated electrically or which received a pressor infusion of noradrenaline were used to study peripheral prejunctional and direct vascular effects, respectively. For studying effects on brain stem cardiovascular regulatory centres, drugs were administered into the cisterna cerebellomedullaris in conscious rabbits. Overall cardiovascular effects of the cannabinoid were studied in conscious rabbits with intravenous drug administration. 3. In pithed rabbits in which the sympathetic outflow was continuously electrically stimulated, intravenous injection of WIN55212-2 (5, 50 and 500 microg kg(-1)) markedly reduced blood pressure, the spillover of noradrenaline into plasma and the plasma noradrenaline concentration, and these effects were antagonized by the CB1 cannabinoid receptor-selective antagonist SR141716A. The hypotensive and the sympathoinhibitory effect of WIN55212-2 was shared by CP55940, another mixed CB1/CB2 cannabinoid receptor agonist, but not by WIN55212-3, the enantiomer of WIN55212-2, which lacks affinity for cannabinoid binding sites. WIN55212-2 had no effect on vascular tone established by infusion of noradrenaline in pithed rabbits. 4. Intracisternal application of WIN55212-2 (0.1, 1 and 10 microg kg(-1)) in conscious rabbits increased blood pressure and the plasma noradrenaline concentration and elicited bradycardia; this latter effect was antagonized by atropine. 5. In conscious animals, intravenous injection of WIN55212-2 (5 and 50 microg kg(-1)) caused bradycardia, slight hypotension, no change in the plasma noradrenaline concentration, and an increase in renal sympathetic nerve firing. The highest dose of WIN55212-2 (500 microg kg(-1)) elicited hypotension and tachycardia, and sympathetic nerve activity and the plasma noradrenaline concentration declined. 6. The results obtained in pithed rabbits indicate that activation of CB1 cannabinoid receptors leads to marked peripheral prejunctional inhibition of noradrenaline release from postganglionic sympathetic axons. Intracisternal application of WIN55212-2 uncovered two effects on brain stem cardiovascular centres: sympathoexcitation and activation of cardiac vagal fibres. The highest dose of systemically administered WIN55212-2 produced central sympathoinhibition; the primary site of this action is not known. (+info)Evaluation of CSF leaks: high-resolution CT compared with contrast-enhanced CT and radionuclide cisternography. (2/221)
BACKGROUND AND PURPOSE: Radiologic evaluation of CSF leaks is a diagnostic challenge that often involves multiple imaging studies with the associated expense and patient discomfort. We evaluated the use of screening noncontrast high-resolution CT in identifying the presence and site of CSF rhinorrhea and otorrhea and compared it with contrast-enhanced CT cisternography and radionuclide cisternography. METHODS: We retrospectively reviewed the imaging studies and medical records of all patients who were evaluated for CSF leak during a 7-year period. Forty-two patients with rhinorrhea and/or otorrhea underwent high-resolution CT of the face or temporal bone and then had CT cisternography and radionuclide cisternography via lumbar puncture. The results of the three studies were compared and correlated with the surgical findings in 21 patients. RESULTS: High-resolution CT showed bone defects in 30 of 42 patients (71%) with CSF leak. High-resolution, radionuclide cisternography and CT cisternography did not show bone defects or CSF leak for 12 patients (29%) who had clinical evidence of CSF leak. Among the 30 patients with bone defects, 20 (66%) had positive results of their radionuclide cisternography and/or CT cisternography. For the 21 patients who underwent surgical exploration and repair, intraoperative findings correlated with the defects revealed by high-resolution CT in all cases. High-resolution CT identified significantly more patients with CSF leak than did radionuclide cisternography and CT cisternography, with a moderate degree of agreement. CONCLUSION: Noncontrast high-resolution CT showed a defect in 70% of the patients with CSF leak. No radionuclide cisternography or CT cisternography study produced positive results without previous visualization of a defect on high-resolution CT. CT cisternography and radionuclide cisternography may be reserved for patients in whom initial high-resolution CT does not identify a bone defect or for patients with multiple fractures or postoperative defects. (+info)Spontaneous cerebrospinal fluid leakage detected by magnetic resonance cisternography--case report. (3/221)
A 49-year-old male with no history of head trauma suffered cerebrospinal fluid (CSF) discharge from the left nostril for one month. Coronal computed tomography (CT) showed lateral extension of the sphenoid sinus on both sides and CSF collection on the left side. CT cisternography could not identify the site of CSF leakage. Heavily T2-weighted magnetic resonance (MR) imaging (MR cisternography) in the coronal plane clearly delineated a fistulous tract through the sphenoid bone into the sphenoid sinus. Patch graft with muscle fragment completely relieved the CSF rhinorrhea. Postoperative three-dimensional CT showed the two bone defects identified during surgery. Small bony dehiscences in the sphenoid bone and lateral extension of the sphenoid sinus predisposed the present patient to CSF fistula formation. MR cisternography in the coronal and sagittal planes is superior to CT scanning or CT cisternography for detection of the site of active CSF leakage. (+info)Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats. (4/221)
The effect of the corticotropin-releasing factor (CRF) receptor antagonists astressin and D-Phe CRF(12-41) injected i.v. on CRF-induced delayed gastric emptying (GE) was investigated in conscious rats. Gastric transit was assessed by the recovery of methyl cellulose/phenol red solution 20 min after its intragastric administration. The 55% inhibition of GE induced by CRF (0.6 microgram i.v.) was antagonized by 87 and 100% by i.v. astressin at 3 and 10 microgram, respectively, and by 68 and 64% by i.v. D-Phe CRF(12-41) at 10 and 20 microgram, respectively. CRF (0.6 microgram)-injected intracisternally (i.c.) induced 68% reduction of GE was not modified by i.v. astressin (10 microgram) whereas i.c. astressin (3 or 10 microgram) blocked by 58 and 100%, respectively, i.v. CRF inhibitory action. Abdominal surgery with cecal manipulation reduced GE to 7.1 +/- 3.1 and 27.5 +/- 3.3% at 30 and 180 min postsurgery, respectively, compared with 40.3 +/- 4.3 and 59.5 +/- 2.9% at similar times after anesthesia alone. Astressin (3 microgram i.v.) completely and D-Phe CRF(12-41) (20 microgram i.v.) partially (60%) blocked surgery-induced gastric stasis observed at 30 or 180 min. The CRF antagonists alone (i.v. or i.c.) had no effect on basal GE. These data indicate that CRF acts in the brain and periphery to inhibit GE through receptor-mediated interaction and that peripheral CRF is involved in acute postoperative gastric ileus; astressin is a potent peripheral antagonist of CRF when injected i.v. whereas i.c. doses >/=3 microgram exert dual central and peripheral blockade of CRF action on gastric transit. (+info)HIV type 1 Nef protein is a viral factor for leukocyte recruitment into the central nervous system. (5/221)
Recombinant HIV-1 Nef protein, but not Tat, gp120, and gp160, provoked leukocyte recruitment into the CNS in a rat model. The strong reduction of bioactivity by heat treatment of Nef, and the blocking effect of the mAb 2H12, which recognizes the carboxy-terminal amino acid (aa) residues 171-190 (but not of mAb 3E6, an anti-Nef Ab of the same isotype, which maps the aa sequence 168-175, as well as a mixture of mAbs to CD4) provided evidence for the specificity of the observed Nef effects. Using a modified Boyden chamber technique, Nef exhibited chemotactic activity on mononuclear cells in vitro. Coadministration of the anti-Nef mAb 2H12, as well as treatment of Nef by heat inhibited Nef-induced chemotaxis. Besides soluble Nef, chemotaxis was also induced by a Nef-expressing human astrocytoma cell line, but not by control cells. These data suggest a direct chemotactic activity of soluble Nef. The detection of elevated levels of IL-6, TNF-alpha, and IFN-gamma in rat cerebrospinal fluid 6 h after intracisternal Nef injection hint at the additional involvement of indirect mechanisms in Nef-induced leukocyte migration into rat CNS. These data propose a mechanism by which HIV-1 Nef protein may be essential for AIDS neuropathogenesis, as a mediator of the recruitment of leukocytes that may serve as vehicles of the virus and perpetrators for disease through their production of neurotoxins. (+info)High-resolution MR cisternography of the cerebellopontine angle, obtained with a three-dimensional fast asymmetric spin-echo sequence in a 0.35-T open MR imaging unit. (6/221)
High-resolution MR cisternography performed with 3D fast asymmetric spin-echo imaging (3D fast spin-echo with an ultra-long echo train length and asymmetric Fourier imaging) was optimized in a 0.35-T open MR imaging unit. The 0.35- and 1.5-T images of the two volunteers and three patients with acoustic schwannomas were then compared. The optimal parameters for images obtained by 3D fast asymmetric spin-echo imaging at 0.35 T were as follows: field of view, 15 cm; matrix, 256 x 256 x 40; section thickness, 1 mm; echo train length, 76; and imaging time, 10 minutes 44 seconds. Scans obtained from both normal volunteers showed the facial, cochlear, and superior and inferior vestibular nerves separately in the internal auditory canal on both 0.35- and 1.5-T images. All three acoustic schwannomas were depicted on both 0.35- and 1.5-T images. Screening for disease at the cerebellopontine angle and in the internal auditory canal, without the administration of contrast material on a low-field open MR imaging unit and within a clinically acceptable imaging time, may be possible. Further controlled prospective studies are required, however, before implementation on a wide basis. If proved effective, this may be of particular value for reducing healthcare costs and for imaging claustrophobic and pediatric patients in an open system. (+info)Neurodevelopmental outcome after antenatal diagnosis of posterior fossa abnormalities. (7/221)
Posterior fossa abnormalities are sonographically diagnosable in the fetus. Anomalies of this region include Dandy-Walker malformation, enlarged cisterna magna, and arachnoid cyst. Despite prenatal diagnosis, the uncertainties related to natural history and neurodevelopmental outcome in survivors make patient counseling difficult. The purposes of this study were to determine the accuracy of prenatal diagnosis of these lesions and elucidate long-term neurodevelopmental outcome in survivors in prenatally diagnosed posterior fossa abnormalities. Fifteen cases of posterior fossa abnormalities were reviewed. Antenatal diagnoses of Dandy-Walker malformation was made in 13 of these cases, arachnoid cyst in one case, and enlarged cisterna magna in one case. Hydrocephalus was present in 66% of patients. The sonographic diagnosis was concordant with the pathologic or neonatal radiologic diagnosis in 13 of 15 cases. Seven fetuses (47%) exhibited additional cranial or extracranial anomalies. A karyotypic abnormality (trisomy 18) was found in one of 15 cases of posterior fossa abnormalities. Neurodevelopmental delay was present in 80% of survivors with follow-up study to 4 years of age. Prenatal diagnosis of posterior fossa abnormalities is highly accurate, yet the differential diagnosis can be challenging. Cognitive and psychomotor developmental delays remain commonplace despite early diagnosis and treatment. The approach with families in cases of prenatal diagnosis of posterior fossa abnormalities should include a search for additional central nervous system and extra-central nervous system anomalies in the fetus and counseling of parents regarding potential adverse outcome for survivors. (+info)Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. (8/221)
Systemic administration of nor-binaltorphimine (nor-BNI) produces a long-lasting kappa-opioid receptor (kappaOR) antagonism and has kappa(1)-selectivity in nonhuman primates. The aim of this study was to establish the pharmacological basis of central kappaOR antagonism in rhesus monkeys (Macaca mulatta). After intracisternal (i.c.) administration of small doses of nor-BNI, the duration and selectivity of nor-BNI antagonism were evaluated against two kappaOR agonists, (trans)-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (U50,488) and bremazocine. Thermal antinociception was measured in the warm water (50 degrees C) tail-withdrawal assay and sedation was evaluated by observers blind to treatment conditions. Following i.c. pretreatment with 0.32 mg nor-BNI, a 5- to 10-fold rightward shift of the U50,488 baseline dose-effect curve was observed in antinociception. In contrast, this dose of nor-BNI only produced an insignificant 2-fold shift against bremazocine. Pretreatment with a smaller dose (0.032 mg) of nor-BNI produced a 3-fold shift of U50, 488, which lasted for 7 days, but failed to alter the potency of bremazocine. This differential antagonism profile of i.c. nor-BNI also was observed in sedation ratings. In addition, the centrally effective dose of nor-BNI (0.32 mg), when administered s.c. in the back, did not antagonize either U50,488- or bremazocine-induced antinociception and sedation. After i.c. pretreatment with the same dose, nor-BNI also did not antagonize the peripherally mediated effect of U50,488 against capsaicin-induced thermal nociception in the tail. These results indicate that i.c. nor-BNI produces central kappaOR antagonism and support the notion of two functional kappaOR subtypes in the central nervous system. Moreover, it provides a valuable pharmacological basis for further characterizing different sources of kappaOR-mediated effects, namely, from central or peripheral nervous system receptors. (+info)The syndrome is named after the American neurologist Dr. Arthur Dandy and British pediatrician Dr. Norman Walker, who first described it in the early 20th century. It is also known as hydrocephalus type I or cerebellar hydrocephalus.
DWS typically affects children, usually girls, between 3 and 18 months of age. The symptoms can vary in severity and may include:
* Enlarged skull
* Abnormal posture and gait
* Delayed development of motor skills
* Intellectual disability
* Seizures
* Vision problems
The exact cause of Dandy-Walker Syndrome is not known, but it is believed to be related to genetic mutations or environmental factors during fetal development. It can occur as an isolated condition or in combination with other congenital anomalies.
There is no cure for DWS, but treatment options may include:
* Shunts to drain excess CSF
* Physical therapy and occupational therapy
* Speech and language therapy
* Seizure medication
* Monitoring with regular imaging studies
The prognosis for children with Dandy-Walker Syndrome varies depending on the severity of the condition and the presence of other medical issues. Some individuals may experience significant developmental delays and intellectual disability, while others may have milder symptoms. With appropriate treatment and support, many individuals with DWS can lead fulfilling lives.
If you suspect vasospasm, it is essential to seek medical attention immediately. A healthcare professional will perform a physical examination and order imaging tests, such as CT or MRI scans, to confirm the diagnosis. Treatment options may include medications to dilate blood vessels, surgery to relieve pressure on affected areas, or other interventions depending on the severity of the condition.
Preventing vasospasm can be challenging, but some measures can reduce the risk of developing this condition. These include managing underlying conditions such as high blood pressure, diabetes, or high cholesterol levels; avoiding head injuries by wearing protective gear during sports and other activities; and adopting a healthy lifestyle that includes regular exercise and a balanced diet.
Early diagnosis and treatment are critical in managing vasospasm and preventing long-term damage to the brain tissue. If you experience any symptoms suggestive of vasospasm, seek medical attention promptly to receive appropriate care and improve outcomes.
This condition can be caused by a variety of factors, such as:
1. Spinal cord injuries or diseases (e.g. spina bifida, multiple sclerosis)
2. Brain injuries or diseases (e.g. cerebral palsy, stroke)
3. Peripheral nerve injuries or diseases (e.g. peripheral neuropathy)
4. Infections (e.g. meningitis, encephalitis)
5. Tumors (e.g. brain tumors, spinal cord tumors)
6. Congenital conditions (e.g. spina bifida)
7. Trauma (e.g. car accidents, falls)
8. Neurodegenerative diseases (e.g. Parkinson's disease, Huntington's disease)
The symptoms of paraparesis, spastic can vary depending on the underlying cause and severity of the condition. Some common symptoms include:
1. Weakness or paralysis of the muscles in the lower limbs
2. Stiffness and resistance to movement (spasticity)
3. Muscle wasting or atrophy
4. Decreased reflexes
5. Loss of sensation in the lower limbs
6. Difficulty with walking, balance, and coordination
7. Spasms or cramps
8. Pain or discomfort
Treatment for paraparesis, spastic depends on the underlying cause and severity of the condition. Some common treatments include:
1. Physical therapy to improve muscle strength and function
2. Occupational therapy to improve daily activities and independence
3. Orthotics or assistive devices to aid with mobility and balance
4. Medications to manage spasticity, pain, or other symptoms
5. Surgery to relieve compression or repair damaged tissue
6. Botulinum toxin injections to reduce muscle spasticity
7. Intrathecal baclofen therapy to reduce muscle spasticity
8. Electrical stimulation therapy to improve muscle function and strength
9. Stem cell therapy to promote repair and regeneration of damaged tissue
10. Alternative therapies such as acupuncture, massage, or yoga to manage symptoms and improve quality of life.
Platybasia can be caused by a variety of factors, including:
1. Chronic inflammation: Prolonged inflammation can cause the basal cells to flatten and spread out, leading to platybasia.
2. Infection: Certain infections, such as herpes simplex virus, can cause platybasia by damaging the epithelial cells.
3. Irritation: Repeated irritation or trauma to the skin or mucous membranes can lead to platybasia.
4. Genetic disorders: Certain genetic disorders, such as epidermolysis bullosa, can cause platybasia by impairing the ability of the epithelial cells to adhere to each other.
5. Cancer: Platybasia can be a feature of some types of cancer, such as squamous cell carcinoma.
The symptoms of platybasia can vary depending on the location and severity of the condition. They may include:
1. Redness and inflammation
2. Thickening of the skin or mucous membranes
3. Formation of scaly or crusted lesions
4. Discharge or bleeding from the affected area
5. Pain or discomfort
The diagnosis of platybasia is typically made through a combination of physical examination, medical history, and diagnostic tests such as biopsy or imaging studies. Treatment depends on the underlying cause of the condition and may include antibiotics, topical medications, or surgery.
In summary, platybasia is a condition characterized by the flattening and spreading out of basal cells in the epithelium, which can be caused by a variety of factors and can occur in various parts of the body. It can cause a range of symptoms and may be associated with certain medical conditions or cancer. Accurate diagnosis and appropriate treatment are important to prevent complications and improve outcomes.
There are several types of Arnold-Chiari malformation, ranging from Type I to Type IV, with Type I being the most common and mildest form. In Type I, the cerebellar tonsils extend into the spinal canal, while in Type II, a portion of the cerebellum itself is pushed down into the spinal canal. Types III and IV are more severe and involve more extensive protrusion of brain tissue into the spinal canal.
The symptoms of Arnold-Chiari malformation can vary depending on the severity of the condition, but may include headaches, dizziness, balance problems, numbness or weakness in the limbs, and difficulty swallowing. The condition is often diagnosed through a combination of physical examination, imaging tests such as MRI or CT scans, and other diagnostic procedures.
Treatment for Arnold-Chiari malformation depends on the severity of the condition and may range from observation to surgery. In mild cases, no treatment may be necessary, while in more severe cases, surgery may be required to relieve pressure on the brain and spinal cord. The goal of surgery is to restore the normal position of the brain and spinal cord and to alleviate symptoms.
In conclusion, Arnold-Chiari malformation is a congenital condition that affects the brainstem and cerebellum, resulting in protrusion of brain tissue into the spinal canal. The severity of the condition varies, and treatment ranges from observation to surgery, depending on the symptoms and severity of the condition.
The exact cause of syringomyelia is not fully understood, but it is believed to be related to abnormal development or blockage of the spinal cord during fetal development. Some cases may be associated with genetic mutations or other inherited conditions, while others may be caused by acquired factors such as trauma, infection, or tumors.
Symptoms of syringomyelia can vary widely and may include:
1. Pain: Pain is a common symptom of syringomyelia, particularly in the neck, back, or limbs. The pain may be aching, sharp, or burning in nature and may be exacerbated by movement or activity.
2. Muscle weakness: As the syrinx grows, it can compress and damage the surrounding nerve fibers, leading to muscle weakness and wasting. This can affect the limbs, face, or other areas of the body.
3. Paresthesias: Patients with syringomyelia may experience numbness, tingling, or burning sensations in the affected area.
4. Spasticity: Some individuals with syringomyelia may experience spasticity, which is characterized by stiffness and increased muscle tone.
5. Sensory loss: In severe cases of syringomyelia, patients may experience loss of sensation in the affected area.
6. Bladder dysfunction: Syringomyelia can also affect the bladder and bowel function, leading to urinary retention or incontinence.
7. Orthostatic hypotension: Some patients with syringomyelia may experience a drop in blood pressure when standing, leading to dizziness or fainting.
Diagnosis of syringomyelia is typically made through a combination of imaging studies such as MRI or CT scans, and clinical evaluation. Treatment options vary depending on the underlying cause and severity of the condition, but may include:
1. Physical therapy to maintain muscle strength and prevent deformities.
2. Orthotics and assistive devices to improve mobility and function.
3. Pain management with medication or injections.
4. Surgery to release compressive lesions or remove tumors.
5. Chemotherapy to treat malignant causes of syringomyelia.
6. Shunting procedures to drain cerebrospinal fluid and relieve pressure.
7. Rehabilitation therapies such as occupational and speech therapy to address any cognitive or functional deficits.
It's important to note that the prognosis for syringomyelia varies depending on the underlying cause and severity of the condition. In some cases, the condition may be manageable with treatment, while in others it may progress and lead to significant disability or death. Early diagnosis and intervention are key to improving outcomes for patients with syringomyelia.
Examples of fetal diseases include:
1. Down syndrome: A genetic disorder caused by an extra copy of chromosome 21, which can cause delays in physical and intellectual development, as well as increased risk of heart defects and other health problems.
2. Spina bifida: A birth defect that affects the development of the spine and brain, resulting in a range of symptoms from mild to severe.
3. Cystic fibrosis: A genetic disorder that affects the respiratory and digestive systems, causing thick mucus buildup and recurring lung infections.
4. Anencephaly: A condition where a portion of the brain and skull are missing, which is usually fatal within a few days or weeks of birth.
5. Clubfoot: A deformity of the foot and ankle that can be treated with casts or surgery.
6. Hirschsprung's disease: A condition where the nerve cells that control bowel movements are missing, leading to constipation and other symptoms.
7. Diaphragmatic hernia: A birth defect that occurs when there is a hole in the diaphragm, allowing organs from the abdomen to move into the chest cavity.
8. Gastroschisis: A birth defect where the intestines protrude through a opening in the abdominal wall.
9. Congenital heart disease: Heart defects that are present at birth, such as holes in the heart or narrowed blood vessels.
10. Neural tube defects: Defects that affect the brain and spine, such as spina bifida and anencephaly.
Early detection and diagnosis of fetal diseases can be crucial for ensuring proper medical care and improving outcomes for affected babies. Prenatal testing, such as ultrasound and blood tests, can help identify fetal anomalies and genetic disorders during pregnancy.
There are several types of hydrocephalus, including:
1. Aqueductal stenosis: This occurs when the aqueduct that connects the third and fourth ventricles becomes narrowed or blocked, leading to an accumulation of CSF in the brain.
2. Choroid plexus papilloma: This is a benign tumor that grows on the surface of the choroid plexus, which is a layer of tissue that produces CSF.
3. Hydrocephalus ex vacuo: This occurs when there is a decrease in the volume of brain tissue due to injury or disease, leading to an accumulation of CSF.
4. Normal pressure hydrocephalus (NPH): This is a type of hydrocephalus that occurs in adults and is characterized by an enlarged ventricle, gait disturbances, and cognitive decline, despite normal pressure levels.
5. Symptomatic hydrocephalus: This type of hydrocephalus is caused by other conditions such as brain tumors, cysts, or injuries.
Symptoms of hydrocephalus can include headache, nausea, vomiting, seizures, and difficulty walking or speaking. Treatment options for hydrocephalus depend on the underlying cause and may include medication, surgery, or a shunt to drain excess CSF. In some cases, hydrocephalus can be managed with lifestyle modifications such as regular exercise and a balanced diet.
Prognosis for hydrocephalus varies depending on the underlying cause and severity of the condition. However, with timely diagnosis and appropriate treatment, many people with hydrocephalus can lead active and fulfilling lives.
Cisterna magna
James Purdon Martin
Dandy-Walker malformation
José Raúl Capablanca
Arne Torkildsen
Subarachnoid cisterns
Cerebellar hypoplasia
Miodrag Radulovacki
Suboccipital puncture
Median aperture
Human brain
3C syndrome
Index of anatomy articles
Aperture (disambiguation)
Pontine cistern
Chudley-Mccullough syndrome
List of MeSH codes (A08)
Sensenbrenner syndrome
Niemann-Pick disease
Colpocephaly
Fourth ventricle
List of regions in the human brain
Lympha
Via Giulia
Beecheria
Saint Roch
List of sister cities in the United States
Roman Catholic Diocese of Ruvo
Prenatal diagnosis of occipital encephalocele, mega-cisterna magna, mesomelic shortening, and clubfeet associated with pure...
Dandy-Walker Malformation Imaging: Practice Essentials, Radiography, Computed Tomography
Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central...
IndexCat
Biomarkers Search
Recording Large-scale Neuronal Ensembles with Silicon Probes in the Anesthetized Rat | Protocol
Refinement Database | Animal Welfare Institute
NIMH » Workshop: Gene-based Therapeutics for Rare Genetic Neurodevelopmental Psychiatric Disorders
MeSH Browser
TREE NUMBER DESCRIPTOR
Pain Commentary - Office of NIH History and Stetten Museum
Chiari II malformation | Radiology Case | Radiopaedia.org
Curso avanzado de ultrasonografÃa: el cerebro fetal y más allá
Bicuculline
Summary Report | CureHunter
DeCS
MeSH Browser
Prefix: mega
NCIt Subset Code NCIt Subset Name NCIt Concept Code NCIt Preferred Term EDQM-HC Preferred Term EDQM-HC Source Code EDQM-HC...
Journal of Hearing Science - Keyword tinnitus
Búsqueda | BVS Bolivia
IMSEAR at SEARO: Search
Gene Therapy • WuXi AppTec Lab Testing Division
Diagnosis and Management of Genetic Derivation 22 and 11 Chromosome-Emanuel Syndrome in 10-Year Old Boy
Bio2Vec
gelstx - European Composites Industry Association Lab GPRMC
Differential Effects of Peripheral versus Central Coadministration of QX-314 and Capsaicin on Neuropathic Pain in Rats |...
IndexCat
CDE Detailed Report | NINDS Common Data Elements
CDE Detailed Report | NINDS Common Data Elements
Lumbar Puncture | Reichman's Emergency Medicine Procedures, 3e | AccessEmergency Medicine | McGraw Hill Medical
Mega-cisterna6
- This case was diagnosed in utero with multiple congenital anomalies including occipital encephalocele, mega-cisterna magna, mesomelic shortening, and clubfeet. (nih.gov)
- Classically, posterior fossa cystic malformations have been divided into Dandy-Walker malformation, Dandy-Walker variant, mega cisterna magna, and posterior fossa arachnoid cyst. (medscape.com)
- Dandy-Walker malformation, variant, and mega cisterna magna are currently believed to represent a continuum of developmental anomalies on a spectrum that has been termed the Dandy-Walker complex. (medscape.com)
- Mega cisterna magna (see the image below) consists of an enlarged posterior fossa secondary to an enlarged cisterna magna, with a normal cerebellar vermis and fourth ventricle. (medscape.com)
- This sagittal T1-weighted MRI shows a large retrocerebellar cerebrospinal fluid collection and a normal fourth ventricle and vermis in a patient with mega cisterna magna in Dandy-Walker malformation. (medscape.com)
- Dandy Walker Variant ,mega cisterna magna,i run these kind games for a baseline of cognitive potential and operate. (unitednationrp.info)
Fourth ventricle3
- Under this term are included a group of conditions that share in common one sonographic findings: the impression that the fourth ventricle communicates with the cisterna magna. (isuog.org)
- From the fourth ventricle, the CSF flows into the cisterna magna via two lateral openings (foramina of Luschka) and one midline opening (foramen of Magendie). (mhmedical.com)
- Note contrast material exiting the fourth ventricle through the foramen of Magendie into the cisterna magna (arrow).G, Axial MR ventriculogram shows contrast material in the lower fourth ventricle exiting the foramen of Magendie. (beilupharma.com)
Subarachnoid Space1
- In a rare case reported by Ciftci et al, multiple intradural cysticercosis were found in the basal cistern, cisterna magna, and cervical subarachnoid space which were isointense with cerebrospinal fluid both on T2 and T1 weighted images Dermoid can be diagnosed by presence of fat and midline in location, epidermoid are bright on spinal difusion where available. (indianradiology.com)
Cerebellum3
- Lemon-shaped skull, banana-shaped cerebellum, obliteration of the cisterna magna, dilated lateral ventricles, and inferior displacement of the brainstem. (radiopaedia.org)
- There is a lemon-shaped skull and banana-shaped cerebellum with obliteration of cisterna manga associated with dilatation of the lateral ventricles. (radiopaedia.org)
- The cisterna magna is located beneath the medulla and cerebellum. (mhmedical.com)
Cerebellar2
- Spirometry was normal, chest x-ray showed features of basal bilateral pulmonary fibrosis, overnight respiratory polygraphy revealed moderate obstructive sleep apnoea, while cerebral magnetic resonance imaging showed a right ventrolateral compression of the medulla oblongata - spinal cord junction by a dominant, sinuous right vertebral artery, and loss of foramen magnum cerebrospinal fluid due to low lying cerebellar tonsils tips, while cisterna magna is still visible. (biomedgrid.com)
- The cisterna magna can be measured from the posterior margin of the cerebellar vermis to the inside of occipital bone in the midline (following an imaginary continuation of the falx). (princeharrymemorial.com)
Cerebrospinal fluid1
- 2022. Chronic collection of cerebrospinal fluid from rhesus macaques (Macaca mulatta) with cisterna magna ports: Update on refinements. (awionline.org)
Mega cisterna magna4
- Classically, posterior fossa cystic malformations have been divided into Dandy-Walker malformation, Dandy-Walker variant, mega cisterna magna, and posterior fossa arachnoid cyst. (medscape.com)
- Dandy-Walker malformation, variant, and mega cisterna magna are currently believed to represent a continuum of developmental anomalies on a spectrum that has been termed the Dandy-Walker complex. (medscape.com)
- Mega cisterna magna (see the image below) consists of an enlarged posterior fossa secondary to an enlarged cisterna magna, with a normal cerebellar vermis and fourth ventricle. (medscape.com)
- This sagittal T1-weighted MRI shows a large retrocerebellar cerebrospinal fluid collection and a normal fourth ventricle and vermis in a patient with mega cisterna magna in Dandy-Walker malformation. (medscape.com)